These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 18177204)

  • 21. A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion.
    Petitdemange C; Achour A; Dispinseri S; Malet I; Sennepin A; Ho Tsong Fang R; Crouzet J; Marcelin AG; Calvez V; Scarlatti G; Debré P; Vieillard V
    Clin Infect Dis; 2013 Sep; 57(5):745-55. PubMed ID: 23696512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
    Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
    J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.
    Vella C; Ferguson M; Dunn G; Meloen R; Langedijk H; Evans D; Minor PD
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2603-7. PubMed ID: 7506299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
    AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.
    Joshi VR; Newman RM; Pack ML; Power KA; Munro JB; Okawa K; Madani N; Sodroski JG; Schmidt AG; Allen TM
    PLoS Pathog; 2020 May; 16(5):e1008577. PubMed ID: 32392227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    Edwards TG; Wyss S; Reeves JD; Zolla-Pazner S; Hoxie JA; Doms RW; Baribaud F
    J Virol; 2002 Mar; 76(6):2683-91. PubMed ID: 11861835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.
    Hicar MD; Chen X; Sulli C; Barnes T; Goodman J; Sojar H; Briney B; Willis J; Chukwuma VU; Kalams SA; Doranz BJ; Spearman P; Crowe JE
    PLoS One; 2016; 11(7):e0158861. PubMed ID: 27411063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.
    Pinter A
    Curr HIV Res; 2007 Nov; 5(6):542-53. PubMed ID: 18045110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.
    Durham ND; Yewdall AW; Chen P; Lee R; Zony C; Robinson JE; Chen BK
    J Virol; 2012 Jul; 86(14):7484-95. PubMed ID: 22553332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.
    Curriu M; Fausther-Bovendo H; Pernas M; Massanella M; Carrillo J; Cabrera C; López-Galíndez C; Clotet B; Debré P; Vieillard V; Blanco J
    PLoS One; 2012; 7(2):e30330. PubMed ID: 22312424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maturation-induced cloaking of neutralization epitopes on HIV-1 particles.
    Joyner AS; Willis JR; Crowe JE; Aiken C
    PLoS Pathog; 2011 Sep; 7(9):e1002234. PubMed ID: 21931551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of HIV gp41-specific antibodies that mediate killing of infected cells.
    Williams KL; Stumpf M; Naiman NE; Ding S; Garrett M; Gobillot T; Vézina D; Dusenbury K; Ramadoss NS; Basom R; Kim PS; Finzi A; Overbaugh J
    PLoS Pathog; 2019 Feb; 15(2):e1007572. PubMed ID: 30779811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.